

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. <b>P8907-9014</b>	SERIAL NO. <b>09/330,215</b>
LIST OF REFERENCES CITED BY APPLICANT  (Use several sheets if necessary)		APPLICANT <b>PORTA et al.</b>	GROUP <b>1614</b>
		FILING DATE <b>June 11, 1999</b>	

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
<i>li</i>	1	4,985,552	01/15/1991	Fedeli et al.	536	27	
<i>li</i>	2	3,770,720	11/06/1973	Butti et al.	260-211.5		


## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
							YES	NO	PART.
<i>li</i>	3	WO 97/04787	02/13/1997	PCT			X		
	4	EP 039471	11/11/1981	Europe			Abstr.		
	5	EP 634384	01/18/1995	Europe			Abstr.		
	6	EP 562509	09/29/1993	Europe			Abstr.		
<i>li</i>	7	EP 539989	05/05/1993	Europe			Abstr.		

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>li</i>	8	Petra Lobel and Karsten Schror, <i>Atherosclerosis</i> , 80; Elsevier Scientific Publishers Ireland, Ltd., "Stimulation of Vascular Prostacyclin and Inhibition of Platelet Function by Oral Defibrotide in Cholesterol-Fed Rabbits", pp. 69-79 (1989)
	9	Katsuhiko Miyasaka and Takashi Mikami, <i>European Journal Pharmacology</i> , 77; Elsevier/North-Holland Biomedical Press, "Comparison of the Anti-Inflammatory Effects of Dexamethasone, Idomethacin and BW755C on Carrageenin-Induced Pleurisy in Rats", pp. 229-236 (1982)
	10	Francis Szoka, Jr. and Demetrios Papahadjopoulos, <i>Proc. Natl. Acad. Sci. USA</i> , vol. 75, no. 9, "Procedure for Preparation of Liposomes with Large Internal Aqueous Space and High Capture by Reverse-Phase Evaporation", pp. 4194-4198 (Sep. 1978)
	11	David C. Litzinger et al., <i>Biochimica et Biophysica Acta</i> , 1281, "Fate of Cationic Liposomes and Their Complex with Oligonucleotide in Vivo", pp. 139-149 (1996)
	12	R.R.C. New, <i>IRL PRESS</i> , "Liposomes, a Practical Approach", pp. 51-54 (1994)
	13	Rollin D. Hotchkiss, <i>Nucleic Acids and Derivatives</i> , "Methods for Characterization of Nucleic Acid", [105] pp. 708-712
	14	Christoph Thiemermann, BSc, et al., <i>The American Journal of Cardiology</i> , "Usefulness of Defibrotide in Protecting Ischemic Myocardium from Early Reperfusion Damage", pp. 978-982 (1985)
	15	Rosario Scalia, et al., <i>Meth Find Exp. Clin Pharmacol</i> , "Effects of Defibortide on Leukocyte-Endothelial Cell Interaction in the Rat Mesenteric Vascular Bed: Role of P-Selectin", 18(10), pp. 669-676 (1996)
	16	Giuseppe Rossoni et al., <i>Journal of Cardiovascular Pharmacology</i> , "Vasoconstriction to Polymorphonuclear Leukocytes in the Isolated, Perfused Rabbit Heart: Inhibition by Prostacyclin Mimetics", 27, pp. 680-685 (1996)
	17	F. Trento, et al., <i>Centro Congressi Unione Industriale</i> , "Interaction of the Endothelial Mediators, No and PGI <sub>2</sub> , on the Regulation of Blood Pressure in Anaesthetized Rats", XXVII Congresso Nazionale Della Societa Italiana Di Farmacologia, Abstracts, Torino, pp. 25-29 (Sep. 1994)
<i>li</i>	18	R. Niada et al., <i>Pharmacological Research Communications</i> , The Italian Pharmacological Society, "PGI <sub>2</sub> -Generation and Antithrombotic Activity of Orally Administered Defibrotide", pp. 949-957 (1982)

19	R. Pescador et al., <i>Thrombosis Research</i> , "Pharmacokinetics of Defibrotide* and of Its Profibrinolytic Activity in the Rabbit", 30, pp.1-11 (1983)
20	Alain Colige et al., <i>Biochemistry</i> , "Use of an Antisense Oligonucleotide to Inhibit Expression of a Mutated Human Porcollagen Gene (COLIA1) IN Transfected Mouse 3T3 Cells", 32, pp. 7-11 (1993)
21	A. Gursoy et al., <i>Pharmazie</i> , "Preparation, Characterization and Anti-Inflammatory Effect of Defibrotide Liposomes", 48, H., pp. 549-550 (1993)
22	Xiang Gao and Leaf Huang, <i>Biochemical and Biophysical Research Communications</i> , "A Novel Cationic Liposome Reagent for Efficient Transfection of Mammalian Cells", vol. 179, no. 1, pp. 280-285 (1991)
23	C. Frank Bennett et al., <i>The American Society for Pharmacology and Experimental Therapeutics</i> , Cationic Lipids Enhance ICAM-1 Antisense Oligonucleotides, "Cationic Lipids Enhance Cellular Uptake and Activity of Phosphorothioate Antisense Oligonucleotides", pp.1023-1033 (1992)
24	Geneve, <i>Informations Pharmaceutiques</i> , vol. 1, no. 4, "Listes Recommandees DCI 27, Denominations communes Internationales Des Substances Pharmaceutiques, Organisation Mondiale de la Sante - Geneve, p. 272 (1987)

EXAMINER	DATE CONSIDERED
	9/11
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

P8907-9014

SERIAL NO.

09/330,215

## LIST OF REFERENCES CITED BY APPLICANT

*(Use several sheets if necessary)*

APPLICANT

PORTA et al.

FILING DATE

June 11, 1999

GROUP

1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO PART.		
	AG	0 558833 A	9-8-93	EP				x	
	AH	90 10448 A8	9-20-90	WO			x		
	AI	96 18372 A	6-20-96	WO			x		
	AJ	97 04787 A	2-13-97	WO			x		
	AK								
	AL								

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AM	<b>ZELPHATI et al.</b> "Cationic Liposomes as an Oligonucleotide Carrier: Mechanism of Action" <u>Journal of Liposome Research, U.S.</u> , Marcel Dekker, NY, January 1, 1997, Vol. 7, No. 1, pp. 31-49.
	AN	
	AO	

EXAMINER

DATE CONSIDERED

\* EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.